AcouSort AB (ticker: ACOU) today announced that the company has been invited to make a presentation at the significant 10th Bioproduction congress in Lyon, France, September 22-23. The company will also exhibit at the congress.

”The Bioproduction Congress is an important annual event of the biopharmaceutical production sector where stakeholders from Europe meet to showcase and exchange the latest innovations in bioprocessing. We are very pleased to be invited to present AcouSort’s novel technology in this quickly developing field”, said Dr. Agnes Michanek, Commercial Director at AcouSort.

Dr. Michanek’s presentation, titled Acoustic Separation Enables High-Quality Bioprocessing for Cell Therapy Manufacturing, is part of the session targeting Breakthrough Innovations in Bioprocessing on September 22.

The congress promotes exchanges on the future of biomanufacturing, addresses the current challenges, and showcases the new breakthrough solutions. This dynamic event gathers experts from companies and laboratories developing therapeutic candidates, as well as leading bioproduction professionals to accelerate the development of therapeutics drugs such as mAbs, vaccines, cell therapy and other novel products into commercial manufacturing.

The agenda addresses the current challenges and development within the bioproduction field and speakers from many of the established companies are presenting their challenges and development for improving production processes and analytics.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Tapper Partners AB.

Attachments
AcouSort invited to present at 10th Bioproduction congress in Lyon

Läs mer på MFN